SYMPLIFY:
Observational study to assess a multi-cancer early detection test in individuals presenting with signs and symptoms of cancer
A study to check the performance of a blood test that may help early identification of different types of cancer and improve patient outcomes.
Background
Cancer is easier to treat if it is diagnosed early. The NHS has developed rapid referral pathways to allow cancers to be diagnosed earlier, but this requires us to run tests on a lot more people than turn out to have cancers. In this study we want to check the performance of a new test, known as GalleriTM, which detects DNA from cancers in the blood.
WHAT WE ARE DOING
Around 6000 people who have been referred by their GP to a rapid referral pathway to see if their symptoms might be due to cancer will be invited to take part. Taking part involves agreeing to a blood test and agreeing that the study team can collect information on the tests and appointments the participant has, their results, plus any diagnosis of symptoms and how that is treated for up to 12 months after enrolment in the study. Participants will not be given the results of their blood test and this will not impact their standard care.
Expected Impact
This study will hopefully develop new blood tests to help early identification of different types of cancer
Results
A plain English summary of our results are available at CRUK:
A trial looking at a new blood test to help diagnose cancer earlier (SYMPLIFY) | Cancer Research UK
This project is funded by GRAIL
Project Members:
-
-
-
-
Pradeep Virdee
NIHR SCPR Post-doctoral Fellow & Medical Statistician
-
PARTNERS ON THIS PROJECT
- Oncology Clinical Trials Unit
- University of Oxford
- Primary Care Clinical Trials Unit
- University of Oxford
- Department of Oncology
- University of Oxford